Multidrug-resistant tuberculosis : tools for tackling a new face of an old foe

Details

• Alternative Title:
  Public health importance of drug-resistant tuberculosis ; Rapid diagnosis of MDR TB: a laboratory systems-based approach ; Rational use of new drugs for treatment of MDR TB: context and challenges ; Drug resistance in TB: what public health can do now and in the future
• Journal Article:
  Public health grand rounds
• Personal Author:
  Shah, N. Sarita ; Shinnick, T. M. (Thomas M.) ; Lienhardt, Christian ; Kenyon, Thomas ; Iskander, John K. ; Laird, Susan
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.). Office of the Associate Director for Communication. ; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of TB Elimination. ; World Health Organization. Stop TB Department. ; Center for Global Health (U.S.)
• Description:
  PDF file of the speakers' PowerPoint presentations at CDC Public health grand rounds: Tuesday, March 18, 2014 at 1 p.m. - 2 p.m.
  
  Tuberculosis is an ancient disease that remains an important global cause of morbidity and mortality. In most cases, TB can be treated and cured by taking a combination of several drugs for 6 to 12 months. When inappropriate or incomplete treatment takes place, however, TB bacteria can develop resistance to multiple drugs. Treatment of drug-resistant TB is currently longer, more toxic, more complex, and less effective than for drug-susceptible TB. In 2011, less than 10% of the total estimated multidrug-resistant TB (MDR TB) cases were detected and annually, there are approximately 500,000 cases of MDR TB, and 150,000 deaths. Although there are simple rapid tests that have improved the diagnosis of the disease, there is immense potential to increase the number of persons diagnosed with MDR TB, and diagnose them more quickly so that they can begin treatment sooner.
  
  Presented by: Sarita Shah, MD, MPH 
Associate Chief for Science, International Research and Programs Branch, Division of TB Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC [“The Public Health Importance of Drug-resistant Tuberculosis”]; Tom Shinnick, PhD 
Associate Director for Global Laboratory Activities, Division of TB Elimination 
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC 
[“Rapid Diagnosis of MDR TB: A Laboratory Systems-based Approach”]; Christian Lienhardt, MD, DTM, MSc, PhD 
Senior Research Advisor, Stop TB Department, 
World Health Organization, Geneva, Switzerland 
[“Rational Use of New Drugs for Treatment of MDR TB: Context and Challenges”]; Tom Kenyon, MD, MPH 
Director, Center for Global Health, CDC
[“Drug Resistance in TB: What Public Health Can Do Now and in the Future”].
  
  Facilitated by: John Iskander, MD, MPH, Deputy Scientific Director, Public Health Grand Rounds, Susan Laird, MSN, RN, Communications Manager, Public Health Grand Rounds.
  
  
• Subjects:
  Drug Resistance, Multiple, Bacterial Microbial Sensitivity Tests/methods Molecular Diagnostic Techniques/methods Tuberculosis, Multidrug-Resistant/diagnosis Tuberculosis, Multidrug-Resistant/drug Therapy
• Series:
  Public Health Grand Rounds
• Document Type:
  Text
• Genre:
  Slides
• Pages in Document:
  68 slides
• Citation:
  Public health grand rounds ; 2014 March 18
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha-512:1786c4f22a37318eb2658bf31e0c5c06c78b2fc1ba4bb0727a865cd81b796d935d165a854ecd94a5f154011400ecc250d53dd2889b6095e79419a449840ae417
• Download URL:
  https://stacks.cdc.gov/view/cdc/22089/cdc_22089_DS1.pdf
• File Type:
  [PDF - 7.21 MB ]